HC Wainwright Forecasts Neurogene FY2027 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Stock analysts at HC Wainwright issued their FY2027 EPS estimates for Neurogene in a report released on Thursday, March 26th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($4.93) per share for the year. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share.

A number of other brokerages have also recently commented on NGNE. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Canaccord Genuity Group initiated coverage on shares of Neurogene in a research note on Friday, February 27th. They set a “buy” rating for the company. Finally, Lifesci Capital started coverage on shares of Neurogene in a report on Monday, January 26th. They set an “outperform” rating and a $50.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Neurogene Stock Performance

NGNE stock opened at $21.41 on Friday. The stock’s 50 day simple moving average is $19.46 and its 200 day simple moving average is $21.65. The company has a market cap of $333.35 million, a P/E ratio of -5.05 and a beta of 1.53. Neurogene has a fifty-two week low of $6.88 and a fifty-two week high of $37.27.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Tuesday, March 24th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.08.

Hedge Funds Weigh In On Neurogene

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in shares of Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after acquiring an additional 978 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after purchasing an additional 1,232 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in Neurogene during the fourth quarter worth about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Neurogene in the 4th quarter worth about $165,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Neurogene

In related news, insider Stuart Cobb sold 6,797 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the completion of the sale, the insider owned 30,497 shares in the company, valued at approximately $634,642.57. This represents a 18.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $84,176.45. Following the completion of the sale, the chief financial officer directly owned 105,798 shares of the company’s stock, valued at $2,201,656.38. The trade was a 3.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 11.64% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.